Ten-Year Experience with Sublingual Immunotherapy for Juniper Pollenosis
Poster Feb 21, 2015
W Donald Cooke MD
RATIONALE: Juniper species are major spring allergens in the southwestern USA. We previously reported a study of sublingual immunotherapy (SLIT) for Juniper pollenosis
in 2005. Over the last ten years, we have gradually expanded the use of SLIT for this allergen. This study summarizes our results.
METHODS: Pollen counts for J. Asheii and J. Scropulorum typically start to rise in mid- March in our area of southwest Colorado. Patients are contacted in early January to
begin the SLIT program. Patients receive 2 vials of J. Scropulorum (Rocky Mountain Juniper, Greer Labs)) extract containing a total of 150-200 micrograms of protein. Maintenance dose is one dropper (6 micrograms) every 3 or 4 days until late May. Patients are instructed to place the drops under the tongue for at least one to two minutes, and then expectorate the remainder. Pollen counts are observed during the season using a Rotorod sampler. Patients are then contacted by phone or office visit in May for assessment of efficacy.
RESULTS: For the 2014 season, 165 patients were treated with Juniper SLIT. 77 of these
patients were monosensitized. 149 (90%) patients reported positive results. Side effects
were mostly local oral discomfort. There were no systemic reactions. In the 2013 season, there were 53 patients reporting 79% positive results.
CONCLUSIONS: Juniper SLIT may be an effective form of immunotherapy when given pre-co-seasonally at the doses studied.
Immunotherapy on Chip: “Under the Microscope” Drug-induced Modulation of the Immune ResponsePoster
The immune system is a striking example of an integrated information system, engaged in coordinated host-protective activities. Organs-on-chip approach (OOC) models allow the direct simultaneous observation of hundreds of different cells, moving, interacting and responding to signals coming from the microenvironment nearby, that give access to a number of parameters describing the system that must be properly measured and elaborated.READ MORE
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
MHV68 Infection in a Novel rag2 F62L/F62L Mouse Model Based on a Patient with CID-G/AI PhenotypePoster
MHV-68 infection in our rag2 mouse model induced increased antibody responses to virus and self and inflammatory disease in end organs. Major mechanism of inflammatory infiltrates and autoantibody generation is yet to be determinedREAD MORE